In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study
- PMID: 25490399
- PMCID: PMC4260959
- DOI: 10.1371/journal.pone.0114866
In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study
Abstract
Introduction: Natural history of chronic obstructive pulmonary disease (COPD) is punctuated by exacerbations; however, little is known about prognosis of the first-ever COPD exacerbation and variables predicting its outcomes.
Materials and methods: A population-based cohort study among COPD patients with their first-ever exacerbations requiring hospitalizations was conducted. Main outcomes were in-hospital mortality and one-year mortality after discharge. Demographics, comorbidities, medications and in-hospital events were obtained to explore outcome predictors.
Results: The cohort comprised 4204 hospitalized COPD patients, of whom 175 (4%) died during the hospitalization. In-hospital mortality was related to higher age (odds ratio [OR]: 1.05 per year; 95% confidence interval [CI]: 1.03-1.06) and Charlson comorbidity index score (OR: 1.08 per point; 95% CI: 1.01-1.15); angiotensin II receptor blockers (OR: 0.61; 95% CI: 0.38-0.98) and β blockers (OR: 0.63; 95% CI: 0.41-0.95) conferred a survival benefit. At one year after discharge, 22% (871/4029) of hospital survivors were dead. On multivariate Cox regression analysis, age and Charlson comorbidity index remained independent predictors of one-year mortality. Longer hospital stay (hazard ratio [HR] 1.01 per day; 95% CI: 1.01-1.01) and ICU admission (HR: 1.33; 95% CI: 1.03-1.73) during the hospitalization were associated with higher mortality risks. Prescription of β blockers (HR: 0.79; 95% CI: 0.67-0.93) and statins (HR: 0.66; 95% CI: 0.47-0.91) on hospital discharge were protective against one-year mortality.
Conclusions: Even the first-ever severe COPD exacerbation signifies poor prognosis in COPD patients. Comorbidities play a crucial role in determining outcomes and should be carefully assessed. Angiotensin II receptor blockers, β blockers and statins may, in theory, have dual cardiopulmonary protective properties and probably alter prognosis of COPD patients. Nevertheless, the limitations inherent to a claims database study, such as the diagnostic accuracy of COPD and its exacerbation, should be born in mind.
Conflict of interest statement
Figures
Similar articles
-
Determining prognosis in acute exacerbation of COPD.Int J Chron Obstruct Pulmon Dis. 2017 Jan 31;12:467-475. doi: 10.2147/COPD.S122382. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28203070 Free PMC article.
-
Predictors of 1-year mortality at hospital admission for acute exacerbations of chronic obstructive pulmonary disease.Respiration. 2013;85(1):15-26. doi: 10.1159/000342036. Epub 2012 Oct 2. Respiration. 2013. PMID: 23037178
-
Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease.Respiration. 2012;84(1):36-43. doi: 10.1159/000331224. Epub 2011 Oct 12. Respiration. 2012. PMID: 21996555
-
The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality: a systematic review and meta-analysis of observational research.Sci Rep. 2015 Nov 10;5:16461. doi: 10.1038/srep16461. Sci Rep. 2015. PMID: 26553965 Free PMC article. Review.
-
Acute exacerbation of COPD: is it the "stroke of the lungs"?Int J Chron Obstruct Pulmon Dis. 2016 Jul 13;11:1579-86. doi: 10.2147/COPD.S106160. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27471380 Free PMC article. Review.
Cited by
-
Disease Trajectories and Impact of One Moderate Exacerbation in Gold B COPD Patients.Int J Chron Obstruct Pulmon Dis. 2022 Mar 16;17:569-578. doi: 10.2147/COPD.S344669. eCollection 2022. Int J Chron Obstruct Pulmon Dis. 2022. PMID: 35321533 Free PMC article.
-
The Long-Term Impact of Frailty After an Intensive Care Unit Admission Due to Chronic Obstructive Pulmonary Disease.Chronic Obstr Pulm Dis. 2024 Jan 25;11(1):83-94. doi: 10.15326/jcopdf.2023.0453. Chronic Obstr Pulm Dis. 2024. PMID: 37931590 Free PMC article.
-
ILC2 Cells Promote Th2 Cell Differentiation in AECOPD Through Activated Notch-GATA3 Signaling Pathway.Front Immunol. 2021 Jun 18;12:685400. doi: 10.3389/fimmu.2021.685400. eCollection 2021. Front Immunol. 2021. PMID: 34354706 Free PMC article.
-
Predictors of 30- and 90-Day COPD Exacerbation Readmission: A Prospective Cohort Study.Int J Chron Obstruct Pulmon Dis. 2021 Oct 7;16:2769-2781. doi: 10.2147/COPD.S328030. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 34675502 Free PMC article.
-
Machine learning approaches for practical predicting outpatient near-future AECOPD based on nationwide electronic medical records.iScience. 2024 Mar 20;27(4):109542. doi: 10.1016/j.isci.2024.109542. eCollection 2024 Apr 19. iScience. 2024. PMID: 38577104 Free PMC article.
References
-
- Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, et al. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187:347–365. - PubMed
-
- Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, et al. (2006) Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27:397–412. - PubMed
-
- Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA (2005) Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171:446–452. - PubMed
-
- Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, et al. (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1418–1422. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical